AU2016385177A1 - Novel fusion protein comprising transcription modulation domain of P65 and protein transport domain and use thereof - Google Patents

Novel fusion protein comprising transcription modulation domain of P65 and protein transport domain and use thereof Download PDF

Info

Publication number
AU2016385177A1
AU2016385177A1 AU2016385177A AU2016385177A AU2016385177A1 AU 2016385177 A1 AU2016385177 A1 AU 2016385177A1 AU 2016385177 A AU2016385177 A AU 2016385177A AU 2016385177 A AU2016385177 A AU 2016385177A AU 2016385177 A1 AU2016385177 A1 AU 2016385177A1
Authority
AU
Australia
Prior art keywords
arg
pro
gly
fusion protein
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2016385177A
Other versions
AU2016385177B2 (en
Inventor
Sang Kyou Lee
Sung Dong Park
Jung-Jin Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Good T Cells Inc
Original Assignee
Good T Cells Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Good T Cells Inc filed Critical Good T Cells Inc
Publication of AU2016385177A1 publication Critical patent/AU2016385177A1/en
Assigned to INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY reassignment INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY Request for Assignment Assignors: LEE, SANG
Assigned to GOOD T CELLS, INC. reassignment GOOD T CELLS, INC. Request for Assignment Assignors: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
Application granted granted Critical
Publication of AU2016385177B2 publication Critical patent/AU2016385177B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to a new fusion protein comprising a transcription modulation domain of p65 which is a subunit of the transcription factor NF-κB, and a protein transport domain and a use thereof. The fusion protein according to the present invention has the effects of inhibiting the transcription of NF-κB and IL-2 by competitive inhibition, inhibiting the secretion of inflammatory cytokines by LPS, and inhibiting the production of IL-2, IFN-γ, IL-4, IL-17A and IL-10 in splenocytes, and thus can be useful as a composition for the prevention or treatment of NF-κB hyperactivity-related diseases.

Description

The invention relates to a new fusion protein comprising a transcription modulation domain of p65 which is a subunit of the transcription factor NF-κΒ, and a protein transport domain and a use thereof. The fusion protein according to the present invention has the effects of inhibiting the transcription of NF-κΒ and IL-2 by competitive inhibition, inhibiting the secretion of inflammatory cytokines by LPS, and inhibiting the production of IL-2, IFN-γ, IL-4, IL17A and IL-10 in splenocytes, and thus can be useful as a composition for the prevention or treatment of NF-κΒ hyperactivity-related diseases.
(57)ri +1¾¾ +1¾¾¾ NF-κΒ ri ri M-If H ri p65 ri +1¾ 2:¾ 2¾¾¾ +(¾¾ ++¾ 2¾¾¾ ri+1 §lri riri riri +1¾¾ 91 riri -8-:+¾ riri 71¾¾.¾ +1¾¾ -0-^-+1¾¾¾¾¾¾ ritiW
51¾¾ NF-κΒ IL-2 ri +1+» ri +1 ri-V, LPS ri riri ririri ririsririri riri> riririri,ririririririri IL-2, IFN-γ, IL-4, IL-17A ri IL-10 ri ^3¾¾ riri riri 5. ri-ri- ririri, nf-kb ri-iiri-Etri ririri riri +¾ ri + arits ri-8-riri riritl ri riri.
wo 2017/119521 Al lllllllllllllllllllllllllllllllllllll^ if A 4.17 <4| ΑΦ AAA:
— AAAA AAA °1AAA /flA ί£Α AAA ΑΆΑ AAA AA A A (A A 4.i7(v))
Ϋ7ΐ|:
— ΑΑΜΜυ^-Α a AA (+/ A 21 2:(3)) — A AAA A AAA AAA AA (A A 5.2(a)) [DESCRIPTION] [Invention Title]
NOVEL FUSION PROTEIN COMPRISING TRANSCRIPTION
MODULATION DOMAIN OF p65 AND PROTEIN TRANSPORT DOMAIN AND
USE THEREOF [Technical Field]
The present invention was made with the support of Future Creation Science division of Korean Government under a subject No. NRF-2014R1A2A1A10052466, 2009-0083522(ERC), 10044494, and with the support of Yonsei University under a subject No. 2015-22-0065. The subject No. NRF-2014R1A2A1A10052466 was conducted under “Middle-Grade Researcher Supporting Project” within the project named “Development of new material for immunological disease customized for Treg, which is the control cell that invigorates the immune system” by “Industry-Academic Cooperation Foundation, YONSEI University” under the management of the National
Research Foundation of Korea, from 1 November, 2014 to 31 October, 2017. The subject No. 2009-0083522(ERC) was conducted under “National Research Foundation of Korea- SRC(Science Research Center)/ERC(Engineering Research Center)” within the project named “ERC/Center for Research on Fulfillment of Protein Function Control (3/3, level 2)” by “Industry-Academic Cooperation Foundation, YONSEI
University” under the management of the National Research Foundation of Korea, from 1 September, 2009 to 29 February, 2016. The subject No. 10044494 was conducted under “SW Computing Industry source technology development project” within the project named “WiseKB: Development of Knowledge Base in Self-study Form Grounded on an Understanding of Bigdata and Deductive Technology” by “Saltlux Inc.” under the management of the Institute for Information &
communications Technology Promotion, from 1 July, 2013 to 28 February, 2016. The subject No. 2015-22-0065 was conducted under “Support for research within the university” within the project named “[Pioneers of the Future - International]
Development of Individually-customized New Medicine made out of Protein, for the
Purpose of Controlling the Function of the Transcription Factor that has the Ability to Control Gene Expression of a Subset of T cell which is a Morfibic factor for Autoimmune Disease” by “ Industry-Academic Cooperation Foundation, YONSEI University” under the management of the Yonsei University, from 1 September 2015 to 31 August, 2016. The present invention relates to a novel fusion protein comprising the transcription modulation domain (TMD) of the transcription factor NFkB subunit p65 and a protein transduction domain (PTD) and to the use thereof.
[Background Art]
Cytokines that are regulated by the transcription factor NF-κΒ include tumor necrosis factor-α (TNF-a), interleukin-1 (IL-1), interleukin-6 and granulocyte15 macrophage colony stimulating factor (GM-CSF), and chemokines that are regulated by NF-κΒ include interleukin-8, macrophage-inflammatory protein-la (MIP-la), methyl accepting chemotaxis protein-1 (MCP-1) and eotaxin. In addition, adhesion molecules that are regulated by NF-κΒ include E-selectin, vascular cell adhesion molecule-1 (VCAM-1), endothelial leukocyte adhesion molecule-1 (ELAM-1) and intercellular cell adhesion molecule-1 (ICAM-1), and inducible enzymes that are regulated by NF-kB include cyclooxygenase-2 (COX-2) and the like. Thus, NF-κΒ is involved in almost all physiological reactions in the body.
The transcription factor NF-κΒ is composed of different subunits composed of homodimers or heterodimers. NF-κΒ proteins include RelA (p65), c-Rel, Rel-B, NF25 kBI (p50) and NF-kB2 (p52), and p50 and p52 are produced from NF-κΒΙ (pl05) and
NF-kB2 (pi00), respectively, which are their precursors. The NF-κΒ proteins each contains about 300 amino acids, called the N-terminal Rel-homology domain (RHD), which is involved in dimerization, binding to specific DNA and reactions with IkB protein. Furthermore, these proteins also contain a nuclear localization signal (NFS) that enables the proteins to act as transcription factors by localization to the nucleus. In addition, the NF-κΒ proteins may be classified, according to the presence or absence of the C-terminal transactivation domain (TAD), into class I (NF-κΒΙ and NF-kB2) and class II (RelA/p65, RelB, and c-Rel). Class II has a transactivation domain that enables the NF-κΒ proteins to act as transcription factors without needing other NF-κΒ domains, and class I has no transactivation domain. Dimers are formed between the NF-kB proteins of the two classes to act as DNA transcription factors. Among the dimers, a p50/p65 dimer is most frequently present. RelA(p65), RelB and c-Rel have a Cterminal transactivation domain, and thus can activate the expression of their target genes. On the contrary, p50 and p52, which are NF-κΒΙ and NF-kB2, respectively, have no ΟΙ 5 terminal transactivation domain, and thus homodimers of p50 and p52 do not act as transcription factors if they do not have bound thereto proteins such as co-activators having a transactivation domain.
A protein transduction domain (PTD) is a short peptide having strong hydrophobicity, and is known to effectively transduce physiologically active molecules such as proteins, DNA and RNA, fused therewith, into cells. The present inventors have developed two PTDs to date, and the PTDs are disclosed in detail in WO 2003059940 and WO 2003059941. Because the protein transduction domain can transduce a physiologically active molecule not only into the cytoplasm but also into the nucleus, it has a property suitable for transducing a modified transcription factor, which is the key substance of the present invention, into the nucleus.
Therefore, the present inventors have attempted to use a fusion protein comprising the transduction modulation domain of the NF-κΒ subunit p65 and a protein transduction domain to inhibit the transcription and activity of NF-κΒ by competitive inhibition to thereby treat effectively a disease caused by NF-κΒ overactivity.
Throughout the specification, a number of publications and patent documents are referred to and cited. The disclosure of the cited publications and patent documents is incorporated herein by reference in its entirety to more clearly describe the state of the related art and the present invention.
[Disclosure] [Technical Problem]
The present inventors have made extensive efforts to develop a substance capable of effectively preventing, alleviating or treating a disease caused by the overactivity of NF-κΒ. As a result, the present inventors have found that, when a fusion protein comprising the transcription modulation domain of the NF-κΒ subunit p65 and a protein transduction domain is used, it can inhibit the transcription and activity of NF-kB by competitive inhibition, thereby completing the present invention.
Therefore, it is an object of the present invention to provide a fusion protein comprising the transcription modulation domain of the NF-κΒ subunit p65 and a protein transduction domain.
Another object of the present invention is to provide an inhibitor of NF-kB transcription or activity, comprising the fusion protein of the present invention.
Still another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of a disease related to NF-κΒ overactivity, the pharmaceutical composition comprising the fusion protein of the present invention as an active ingredient.
Still another object of the present invention is to provide a method for inhibiting transcription or activity of NF-κΒ, and a method of preventing, improving or treating a disease related to NF-κΒ overactivity.
Other objects and advantages of the present invention will become more apparent from the following detailed description, the appended claims and the accompanying drawings.
[Technical Solution]
In accordance with one aspect of the present invention, there is provided a fusion 10 protein comprising the transcription modulation domain of the NF-κΒ subunit p65 and a protein transduction domain. The fusion protein of the present invention inhibits NF-kB transcription by competitive inhibition.
The present inventors have made extensive efforts to develop a substance capable of effectively preventing, alleviating or treating a disease caused by NF-kB overactivity. As a result, the present inventors have found that, when a fusion protein comprising the transcription modulation domain of the NF-κΒ subunit p65 and a protein transduction domain is used, it can inhibit the transcription and activity of NF-κΒ by competitive inhibition.
As used herein, the term “transcription modulation domain” means a portion of a transcription factor, which is composed only of a DNA binding domain without a transactivation domain. As demonstrated in the examples below, the fusion protein of the present invention has no transactivation domain, but has a DNA binding domain, and thus it can bind to a target promoter, but cannot promote transcription. Accordingly, the fusion protein of the present invention is a dominant negative mutant for the NF-κΒ gene, and thus can act as a competitive inhibitor against wild-type NF-κΒ in cells to inhibit the transcription and activity of NF-kB.
In one embodiment, NF-κΒ that is used in the present invention is NF-kB selected from the group consisting of RelA (p65), c-Rel, Rel-B, NF-κΒΙ (p50) and NFkB2 (p52). In a specific embodiment, NF-κΒ that is used in the present invention is
RelA (p65).
In one embodiment, the transcription modulation domain of NF-κΒ that is used in the present invention comprises an amino acid sequence of SEQ ID NO: 1. In another embodiment of the present invention, the transcription modulation domain of NF-κΒ, which comprises the amino acid sequence of SEQ ID NO: 1, is encoded by a nucleotide sequence of SEQ ID NO: 3.
As used herein, the term “protein transduction domain” is a short, strongly hydrophobic peptide consisting of 7-50 amino acids, and means a domain capable of transducing not only a protein having a molecular weight of 120 kDa or more, but also DNA or RNA, into cells. As demonstrated in the examples below, it could be seen that, unlike the fusion protein of the present invention, a protein to which the protein transduction domain of the present invention is not attached (that is, p65-TMD composed only of the transcription modulation domain) has no effects on the inhibition of transcription of NF-κΒ and IF-2, the inhibition of FPS-induced secretion of inflammatory cytokines, and the inhibition of production of IF-2, IFN-γ, IF-4, IF-17A and IF-10 in splenocytes.
According to one embodiment of the present invention, the protein transduction domain that is used in the present invention is selected from the group consisting of Hph1, Sim-2, Tat, VP22, Antp (antennapedia), Pep-1 (peptide-1), PTD-5 (protein transduction domain-5), 7R, 9R, 11R and CTP (cytoplamic transduction peptide). As used herein, the terms “7R”, “9R” and “11” mean peptides consisting of 7, 9 and 11 arginine residues, respectively. According to a specific embodiment, the protein transduction domain that is used in the present invention is Hph-1.
According to one embodiment of the present invention, the protein transduction domain that is used in the present invention comprises an amino acid sequence of SEQ
ID NO: 2. According to another embodiment of the present invention, the protein transduction domain comprising the amino acid sequence of SEQ ID NO: 2 according to the present invention is encoded by a nucleotide sequence of SEQ ID NO: 4.
According to one embodiment of the present invention, the fusion protein of the present invention comprises an amino acid sequence of SEQ ID NO: 5. According to a specific embodiment of the present invention, a fusion protein comprising an amino acid sequence of SEQ ID NO: 5 is encoded by a nucleotide sequence of SEQ ID NO: 6.
In accordance with another aspect of the present invention, there is provided an inhibitor of NF-κΒ transcription or activity, comprising the fusion protein of the present invention. As demonstrated in the examples below, it was shown that the fusion protein of the present invention could inhibit the transcription and activity of NF-κΒ and IL-2 (FIG. 6), inhibit the LPS-induced secretion of inflammatory cytokines (FIG. 7), and inhibit the production of IL-2, IFN-γ, IL-4, IL-17A and IL-10 which are expressed by Tcell activation stimulated by anti-CD3/CD28 in splenocytes (FIG. 9), indicating that the fusion protein can inhibit the NF-KB-induced proliferation and differentiation of T cells and the NF-KB-induced secretion of inflammatory cytokines. This suggests that the fusion protein of the present invention can effectively prevent, alleviate or treat a disease caused by the overactivity of NF-kB.
In accordance with another aspect of the present invention, there is provided a pharmaceutical composition for the prevention or treatment of a disease related to NF-kB overactivity, the pharmaceutical composition comprising the fusion protein of the present invention as an active ingredient.
As used herein, the term treatment refers to: (a) suppressing the progression of disease, disorder, or symptom; (b) reducing disease, disorder, or symptom; or (c) curing the disease, disorder, or symptom. The composition of the present invention suppresses the development of symptoms of metabolic disease, or removes or reduces the symptoms of metabolic disease. Therefore, the composition of the present invention may be a composition for treating disease related to NF-κΒ overactivity, or may be applied as a treatment adjuvant for the disease when administered with other composition for treating a disease related to NF-κΒ overactivity. As used herein, the term treatment or treatment agent includes a meaning of treatment aid or therapeutic adjuvant.
As demonstrated in the examples below, the fusion protein of the present invention inhibits the transcription of NF-κΒ and IL-2, inhibits the LPS-induced secretion of inflammatory cytokines, and inhibits the production of IL-2, IFN-γ, IL-4, IL17A and IL-10 in splenocytes. Thus, the fusion protein of the present invention may be effectively used as a composition for efficiently preventing or treating various diseases related to NF-κΒ overactivity.
In one embodiment of the present invention, the disease related to NF-κΒ overactivity in the present invention is an inflammatory disease or an autoimmune disease. In another embodiment of the present invention, the disease related to NF-κΒ overactivity in the present invention is a disease selected from the group consisting of septic shock, allergic asthma, allergic nasitis, atopic dermatitis, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, dacryoadenitis, Alzheimer's disease, stroke, arteriosclerosis, vascular restenosis, type I diabetes, type II diabetes, urticaria, conjunctivitis, psoriasis, systemic inflammatory response syndrome, polymyositis, dermatomyositis, polyarthritis nodosa, mixed connective tissue disease,
Sjogren's syndrome, gout, Parkinson's disease, amyotrophic lateral sclerosis, diabetic retinopathy, multiple sclerosis, Crohn's disease, chronic thyroiditis, Celiac disease, myasthenia gravis, pemphigus vulgaris, viral diseases, bacterial diseases, radiationinduced disorders, arteriosclerosis, hemangioma, angiofibroma, reperfusion injury, and cardiac hypertrophy. According to a specific embodiment, the disease related to NF-kB overactivity in the present invention is septic shock. Septic shock that causes a severe systemic inflammatory reaction due to microbial infection shows abnormalities in the cardiovascular system and vasomotor factors by endotoxins and inflammatory mediators circulating the blood vessels. For this reason, hypovolemia occurs due to dehydration and leakage of intravascular liquid, and vascular contraction and relaxation in capillary vessels occur to cause abnormalities in blood supply, and vasculitis and thrombosis make tissue reflux more difficult, resulting in tissue hypoxia and metabolic acidosis. In particular, endotoxins activate NF-κΒ in immunocytes (macrophages, granulocytes, dendritic cells, and lymphocytes) to secrete cytokines such as tumor necrosis factor, linterleukin-1 and linterleukin-6, and such cytokines stimulate neutrophils, endothelial cells, platelets or inflammatory mediator-releasing cells to cause systemic reactions. As demonstrated in the examples below, it was shown that the fusion protein of the present invention inhibited the secretion of inflammatory cytokines in septic shock models induced by LPS and increased the survival rate of the models (FIG. 10).
Thus, it can be seen that the fusion protein of the present invention is effective for the prevention or treatment of a disease related to NF-κΒ overactivity.
If the composition of the present invention is prepared as a pharmaceutical composition, the pharmaceutical composition of the present invention contains a pharmaceutically acceptable carrier. Examples of the pharmaceutically acceptable carrier that is contained in the pharmaceutical composition of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil, which are commonly used in formulations. The pharmaceutical composition may further contain, in addition to the above-described components, a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative or the like. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).
The pharmaceutical composition of the present invention may be administered orally or parenterally. When the pharmaceutical composition is administered parenterally, it may be injected intravenously, subcutaneously, intramuscularly, intraperitoneally, transdermally, or the like. In one embodiment of the present invention, the pharmaceutical composition of the present invention may be administered by intraperitoneal injection.
The suitable dose of the pharmaceutical composition of the present invention may vary depending on various factors, including the formulation method, the mode of administration, the patient’s age, weight, sex, disease condition and diet, the time of administration, the route of administration, the rate of excretion, and reaction sensitivity.
The daily dose of the pharmaceutical composition according to the present invention is, for example, 0.0001-1000 mg/kg.
The pharmaceutical composition of the present invention may be formulated with a pharmaceutically acceptable carrier and/or excipient in a unit dosage form or a multiple dosage form, according to a method that can be easily carried out by a skilled person in the art to which the present invention pertains. Herein, the formulation may be a solution in oil or an aqueous medium, a suspension, syrup, an emulsifying solution, an extract, powder, granules, a tablet, or a capsule, and may further contain a dispersing agent or a stabilizing agent.
Because the NF-κΒ transcription or activity inhibitor of the present invention and the composition for the prevention or treatment of a disease related to NF-κΒ overactivity according to the present invention commonly comprise the above-described fusion protein, the description of the contents that are common in relation to the fusion protein is omitted in order to avoid excessive complexity of description.
In accordance with another aspect of the present invention, there is provided a method of inhibiting transcription or activity of NF-κΒ, the method comprising administering a composition comprising the fusion protein of the present invention as an active ingredient.
In accordance with another aspect of the present invention, there is provided a method of preventing, improving or treating a disease related to NF-κΒ overactivity, the method comprising administering, to a subject in need, a composition comprising the fusion protein of the present invention as an active ingredient.
As used herein, the term administration or administer refers to a method wherein a therapeutically effective amount of the composition of the present invention is directly administered to a subject to form the same amount thereof in the body of the subject. Therefore, the term administer includes the injection of an active ingredient (the fusion protein of the present invention) around a site of lesion, and thus the term administer is used in the same meaning as the term inject.
The term therapeutically effective amount of the composition refers to the content, which is sufficient to provide a therapeutic or prophylactic effect to a subject to be administered, and thus the term has a meaning including prophylactically effective amount. As used herein, the term subject includes, but is not limited to, human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, monkey, chimpanzee, beaver, or rhesus monkey. Specifically, the subject of the present invention is human.
Since the method of inhibiting the transcription or activity NF-κΒ, and the method for preventing, improving or treating the disease related to NF-κΒ overactivity commonly comprise the above-described fusion protein and the use thereof, descriptions of overlapping contents therebetween are omitted to avoid excessive complication of the specification due to repeated descriptions thereof.
[Advantageous Effects]
The features and advantages of the present invention are as follows.
(a) The present invention provides a fusion protein comprising the transcription modulation domain of the NF-κΒ subunit p65 and a protein transduction domain, and the use thereof.
(b) The fusion protein of the present invention has the effects of inhibiting the transcription of NF-κΒ and IF-2 by competitive inhibition and inhibiting the FPS20 induced secretion of inflammatory cytokines and also inhibiting the production of IF-2, IFN-γ, IF-4, IF-17A and IF-10 in splenocytes, and thus can be effectively used as a composition for the prevention or treatment of a disease related to NF-κΒ overactivity.
[Description of Drawings]
FIG. 1 shows the structure of a fusion protein (nt-p65-TMD) of a p6525 transcription modulation domain (p65-TMD) and Hph-1 (PTD) according to an embodiment of the present invention. DBD: DNA binding domain; IBD: IkB binding domain; NLS: nuclear localization sequence; TAD: transactivation domain.
FIG. 2 shows the results of Coomassie blue staining of the fusion protein (ntp65-TMD) according to the present invention.
FIG. 3 shows the results of transduction of the fusion protein (nt-p65-TMD) of the present invention into BV2 and Jurkat T cells.
FIG. 4 shows the results of transduction of the fusion protein (nt-p65-TMD) of the present invention into the nuclei of BV2 and HeFa cells.
FIG. 5 shows the results of cytotoxicity of the fusion protein (nt-p65-TMD) of the present invention in BV2 and spleen cells.
FIG. 6 shows the effect of the fusion protein (nt-p65-TMD) of the present invention on competitive inhibition of transcription.
FIG. 7 shows the effect of the fusion protein (nt-p65-TMD) of the present invention on the inhibition of FPS-induced expression of TNF-α, IL-1 β and IF-6.
FIG. 8a shows results indicating that the fusion protein (nt-p65-TMD) of the present invention specifically inhibits NF-κΒ transcription induced by T-cell activation stimulated by anti-CD3/CD28. FIG. 8b show results indicating that fusion protein (ntp65-TMD) of the present invention does not influence signal transduction pathways induced by T-cell activation stimulated by anti-CD3/CD28.
FIG. 9 shows results indicating that the fusion protein (nt-p65-TMD) of the present invention inhibits the expression of IF-2, IFN-γ, IF-4, IF-17A and IF-10, induced by T-cell activation stimulated by anti-CD3/CD28.
FIG. 10 shows results indicating that the fusion protein (nt-p65-TMD) of the present invention inhibits the secretion of inflammatory cytokines (TNF-α, IL-1 β and IF25 6) in septic shock animal models to thereby increase the survival rate of the animal models.
[Best Mode]
Hereinafter, the present invention will be described in further detail with reference to examples. It will be obvious to those skilled in the art that these examples are for illustrative purposes and are not intended to limit the scope of the present invention.
Examples
Example 1: Preparation of a Recombinant Fusion Protein Comprising p65 Transcription Modulation Domain and Protein Transduction Domain
The protein transduction domain (PTD) Hph-1 (SEQ ID NO: 4) was cloned into the p65 transcription modulation domain p65-TMD (SEQ ID NO: 2) and a pET-28a(+) vector (Novagen) to thereby construct a recombinant fusion DNA (nt-p65-TMD) (SEQ ID NO: 6). The recombinant fusion DNA was transformed into a BL21 CodonPlus(DE3)-RIPL E. coli strain (Invitrogen). The transformed strain was cultured, and then treated with 1 mM IPTG (isopropyl-[l-D-thiogalactopyranosidc, Duchefa), after which protein expression in the strain was induced at 37°C for 5 hours. Next, only the cells were harvested, lysed with lysis buffer (10 mM imidazole, 50 mM NaH2PO4, 300 mM NaCl, pH 8.0), and then disrupted with a homogenizer. The fusion protein was bound to Ni-NTA beads (Qiagen) by 6 histidine residues linked to the upstream region of the protein. The protein was loaded onto HisTrap chromatography columns (Bio-Rad), and washed sufficiently with washing buffer (30 mM imidazole, 50 mM NaH2PC>4, 300 mM NaCl, pH 8.0), and the protein was eluted with elution buffer (250 mM imidazole, 50 mM NaH2PO4, 300 mM NaCl and pH 8.0). Using PD-10 Sephadex G-25 (GE Healthcare), imidazole and NaCl were removed while the buffer was replaced with 10% glycerol-containing PBS. Because the obtained protein contained endotoxins such as
LPS, it was purified once more using SP beads (SP Sepharose™ Fast Flow, GE
Healthcare) to remove the endotoxins. The resulting protein was bound using binding buffer (50 mM NafFPCU 300 mM NaCl, pH 6.0), and then loaded onto a column and eluted with elution buffer (50 mM NafFPCfi, 2 M NaCl, pH 6.0). Finally, NaCl was removed using PD-10 Sephadex G-25, and the buffer was placed with 10% glycerolcontaining PBS, after which the resulting protein (SEQ ID NO: 5, recombinant fusion protein) was stored at 80°C until use in experiments (see FIGS. 1 and 2).
Example 2: Analysis of Intracellular Transduction of nt-p65-TMD
Recombinant Fusion Protein
2-1: Analysis of Intracellular Transduction by Western Blotting
BV2 microglial cells and Jurkat T cells were incubated with the recombinant fusion protein (nt-p65-TMD) at varying protein concentrations (0, 0.1, 0.5, 1, 2 and 5 μΜ) or for varying times (0, 1, 2, 4, 6, 12, 24 and 48 hours), and whether or not the fusion protein was transduced was analyzed by Western blotting.
As a result, it was shown that the fusion protein was well transduced in proportion to the concentration thereof and was continuously transduced even at 48 hours while the protein in the cell culture maintained its structure (see FIG. 3).
2-2: Analysis of Whether or Not Fusion Protein is Transduced to Nucleus of Cells, by Use of Antibody
5 μΜ of the recombinant fusion protein (nt-p65-TMD) of Example 1 was incubated with BV2 microglial cells and HeLa cells for 1 hour and washed with PBS, after which the cells were treated with 0.2% Triton X-100 (Sigma-Aldrich) to form an opening, and a fluorescence-labeled antibody was bound to the recombinant fusion protein through the opening. Next, the nucleus of the cells was stained with DAPI dye (Invitrogen), and then the location of fluorescence was determined by a fluorescence microscope to thereby determine the location to which the recombinant fusion protein was transduced.
As a result, it was shown that the fusion protein was well transduced to the nucleus of the cells by the property of the PTD (see FIG. 4).
Example 3: Analysis of Cytotoxicity of nt-p65-TMD Recombinant Fusion
Protein
In order to confirm that the protein obtained from the E. coli strain by expression is completely free of FPS so that it is not toxic to cells or animals, a cytotoxicity test was performed. Varying concentrations of the protein were transduced into BV2 microglial cells and splenocytes, and then the cells were incubated with WST-8, a substrate that develops color by dehydrogenase present in living cells.
As a result, it could be seen that the cells treated with the fusion protein showed no cytotoxicity regardless of the concentration of the fusion protein, unlike cells not treated with the protein (FIG. 5).
Example 4: Confirmation of the Effect of nt-p65-TMD Recombinant Fusion Protein on Specific Inhibition of Transcription Factor
4-1: Confirmation of Inhibitory Effect against Transcription of NF-κΒ and
IL-2 in HEK293T Cells
To directly confirm whether or not the nt-p65-TMD recombinant fusion protein of Example 1 binds to the promoters of the NF-κΒ and IF-2 cytokine genes in place of wild-type p65 to inhibit the expression of the genes, luciferase reporter gene was used. First, each of NF-κΒ and IF-2 promoters and wild-type p65 gene, which have luciferase in the downstream region, was transfected into the nucleus of HEK293T cells, and then the cells were treated with the nt-p65-TMD recombinant fusion protein.
As a result, it could be seen that, when the cells were treated with the recombinant fusion protein, the expression of luciferase in the cells was effectively inhibited. This suggests that nt-p65-TMD acted as a competitive inhibitor of wild-type p65 to block the p65-binding site of each of the NF-κΒ and IL-2 promoters (see FIG. 6).
4-2: Confirmation of Inhibitory Effect against Secretion of Inflammatory 5 Cytokines in BV2 Microglial Cells
BV2 microglial cells were treated with the nt-p65-TMD recombinant fusion protein of Example 1, and after 1 hour, the cells were treated and incubated with LPS (1 pg/ml, E. coli serotype O55:B5, Sigma-Aldrich) for 24 hours.
As a result, it could be seen that the expression of TNF-α, IL-1 β and IL-6, which 10 are activated and expressed by LPS, was inhibited by the nt-p65-TMD recombinant fusion protein (see FIG. 7).
4-3: Confirmation of Specific Inhibitory Effect against NF-κΒ Transcription
Factor in Jurkat T Cells
Whether or not the nt-p65-TMD recombinant fusion protein of Example 1 15 specifically inhibits the transcription of NF-κΒ activated by Jurkat T-cell activation stimulated by anti-CD3 (1 pg/ml, BD Pharmingen) and anti-CD28 (1 pg/ml, BD Pharmingen) was examined. When T cells are activated, not only NF-κΒ transcription but also NFAT transcription is activated. For this reason, if the nt-p65-TMD fusion protein inhibits only NF-κΒ transcription without influencing NFAT transcription, it can be seen that the nt-p65-TMD recombinant fusion protein acts as a specific competitive inhibitor of NF-κΒ. To confirm this fact, luciferase reporter gene was used. First, NFkB and NFAT reporter genes having luciferase in the downstream region were transfected into the nucleus of Jurkat T cells by elctroporation, and then the Jurkat T cells were stimulated with anti-CD3 and anti-CD28 and treated with the nt-p65-TMD recombinant fusion protein.
As a result, it could be seen that, when the NF-KB-transfected cells were treated with the recombinant fusion protein, the expression of luciferase in the cells was effectively inhibited, but NF AT was not influenced by the recombinant fusion protein (see FIG. 8a).
4-4: Phosphorylation of Intracellular Signal Transduction Protein
In order to examine whether or not the nt-p65-TMD recombinant fusion protein of Example 1 is involved in tyrosine phosphorylation of proteins related to various intracellular signal transduction systems, Western blot analysis was performed. Jurkat T cells were treated with 2 μΜ of nt-p65-TMD for 1 hour, and then stimulated with antiCD3 (2.5 μg/ml) and anti-CD28 (2.5 μg/ml), and whether or not tyrosine phosphorylation of ZAP-70, p38, JNK or ERK occurred was observed.
As a result, it could be seen that nt-p65-TMD did not influence phosphorylation of these proteins (see FIG. 8b).
4-5: Inhibition of Production of Cytokines (IL-2, IFN-γ, IL-4, IL-17A and IL-10) in Splenocytes
Splenocytes isolated from the spleens of 6-8-week-old female C57BL/6 mice were treated with the nt-p65-TMD recombinant fusion protein of Example 1 for 1 hour to transduce the recombinant fusion protein into the cells. The cells were stimulated with anti-CD3 (1 pg/ml) and anti-CD28 (1 pg/ml), and then incubated for 72 hours. Next, the amounts of cytokines present in the medium were measured by ELISA.
As a result, it could be seen that, when the cells were treated with nt-p65-TMD, the expression levels of IL-2, IFN-γ, IL-4, IL-17A and IL-10 in the cells were greatly inhibited. In addition, the expression level of CD69, which is indicative of T cell activation, was measured by FACS Calibur (BD Biosciences), and as a result, it could be seen that nt-p65-TMD did not influence the expression of CD69 in T cells (FIG. 9).
Example 5: Evaluation of Therapeutic Effect of nt-p65-TMD in Septic
Shock Animal Models
LPS (20 mg/kg) was injected intraperitoneally into 6-8-week-old male BALB/c mice to make septic shock animal models. After 2 hours and 14 hours, the nt-p65-TMD recombinant fusion protein of Example 1 was injected intraperitoneally into the animal models, followed by observation for 6 days.
As a result, it could be seen that, when the animal models were treated with ntp65-TMD, the secretion of inflammatory cytokines (TNF-a, IL-Ιβ and IL-6) was inhibited to thereby greatly increase the survival rate of the animal models (see FIG. 10).
Example 6: Acute Toxicity Test for Recombinant Fusion Protein
Using 6-week-old specific pathogen-free (SPF) rats obtained from the Daehan Experiment Supply Center, an acute toxicity test was performed in the following manner. The recombinant fusion protein of Example 1 was administered orally once to each animal group (consisting of two animals) at a dose of 1 g/kg, and then the death, clinical symptoms and weight changes of the animals were observed, and hematological tests and blood biochemical tests were performed. In addition, the animals were autopsied, and whether or not the abdominal organs and the thoracic organs were abnormal was visually observed.
As a result, in all the animals administered with the test substance, specific clinical symptoms or dead animals were not found, and in the weight change measurement, hematological tests, blood biochemical tests and autopsy findings, no change in toxicity was observed. Thus, it could be seen that the recombinant fusion protein of the present invention showed no toxicity in the rats even at a dose of 1 g/kg and that the minimum lethal dose (LD50) upon oral administration thereof was 1 g/kg or more, suggesting that it is a safe substance.
References
Park et al., Intranuclear interactomic inhibition of NF-kB suppresses FPSinduced severe sepsis, Biochemical and Biophysical Research Communications, 2015;
464:711-717.
Although the present disclosure has been described in detail with reference to the specific features, it will be apparent to those skilled in the art that this description is only of a preferred embodiment thereof, and does not limit the scope of the present invention. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.

Claims (16)

  1. [CLAIMS]
    1. A fusion protein comprising a transcription modulation domain of NFkB and a protein transduction domain, wherein the fusion protein inhibits NF-kB transcription by competitive inhibition.
  2. 2. The fusion protein of claim 1, wherein the NF-κΒ is NF-κΒ selected from the group consisting of RelA (p65), c-Rel, Rel-B, NF-κΒΙ (p50) and NF-kB2 (p52).
  3. 3. The fusion protein of claim 1, wherein the NF-κΒ is RelA (p65).
  4. 4. The fusion protein of claim 1, wherein the transcription modulation domain of NF-κΒ comprises an amino acid sequence of SEQ ID NO: 1.
  5. 5. The fusion protein of claim 4, wherein the transcription modulation domain of NF-κΒ is encoded by a nucleotide sequence of SEQ ID NO: 3.
  6. 6. The fusion protein of claim 1, wherein the protein transduction domain is selected from the group consisting of Hph-1, Sim-2, Tat, VP22, Antp (antennapedia), Pep-1 (peptide-1), PTD-5 (protein transduction domain-5), 7R, 9R, 11R and CTP (cytoplasmic transduction peptide).
  7. 7. The fusion protein of claim 1, wherein the protein transduction domain is Hph-1.
  8. 8. The fusion protein of claim 1, wherein the protein transduction domain comprises an amino acid sequence of SEQ ID NO: 2.
  9. 9. The fusion protein of claim 8, wherein the protein transduction domain is encoded by a nucleotide sequence of SEQ ID NO: 4.
  10. 10. The fusion protein of claim 1, wherein the fusion protein comprises an amino acid sequence of SEQ ID NO: 5.
  11. 11. The fusion protein of claim 10, wherein the fusion protein is encoded by a nucleotide sequence of SEQ ID NO: 6.
  12. 12. An inhibitor of NF-κΒ transcription or activity, comprising the fusion protein of claim 1.
  13. 13. A pharmaceutical composition for prevention or treatment of a disease related to NF-κΒ overactivity, the composition comprising the fusion protein of claim 1 as an active ingredient.
  14. 14. The composition of claim 13, wherein the disease related to NF-kB overactivity is an inflammatory disease or an autoimmune disease.
  15. 15. The composition of claim 13, wherein the disease related to NF-kB overactivity is a disease selected from the group consisting of septic shock, allergic asthma, allergic nasitis, atopic dermatitis, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, dacryoadenitis, Alzheimer's disease, stroke, arteriosclerosis, vascular restenosis, type I diabetes, type II diabetes, urticaria, conjunctivitis, psoriasis, systemic inflammatory response syndrome, polymyositis, dermatomyositis, polyarthritis
    5 nodosa, mixed connective tissue disease, Sjogren's syndrome, gout, Parkinson's disease, amyotrophic lateral sclerosis, diabetic retinopathy, multiple sclerosis, Crohn's disease, chronic thyroiditis, Celiac disease, myasthenia gravis, pemphigus vulgaris, viral diseases, bacterial diseases, radiation-induced disorders, arteriosclerosis, hemangioma, angiofibroma, reperfusion injury, and cardiac hypertrophy.
  16. 16. A method for inhibiting transcription or activity of NF-κΒ, the method comprising administering a composition comprising the fusion protein of claim 1 as an active ingredient.
    15 17. A method of preventing, improving or treating a disease related to NF-kB overactivity, the method comprising administering, to a subject in need, a composition comprising the fusion protein of claim 1 as an active ingredient.
    1/8
    Fig. 1
    195 ; Hph-1-PTD (YARVRRRGPRR) nt-p65-TMD: nucleus-transducible p65-transcription modulation domain mnt-p65-TMD: mutant form of nt-p65-TMD
    Fig. 2
    Lanel: p65-TMD Lane2: nt-p65-TMD Lane3: mnt-p65-TMD
    2/8
    Fig. 3a tyr A' A A' A' AT ,o* # x* .XT ty? ty?
    0 <T <v <r <v
    FLAG β-actin
    FLAG β-actin
    Fig. 3b nt-p85-TMD<2 pM)
    0 1 2 4 6 12 24 48 (h)
    FLAG β-actin
    FLAG β-actin
    3/8
    Fig. 4
    4/8
    Fig. 5
    BV2
    Cell Viability (%) Cell Viability {%)
    5/8
    Fig. 6
    Fig. 7
    LPS
    LPS
    LPS
    6/8
    Fig. 8a
    Relative NFKB1 luciferase activity (%)
    NS
    Anti-CD3/CD28
    Fig. 8b p-ERK β-actin
    7/8
    Fig. 9
    X.-* rngftnf) C*lr* of Mux) Co**/,A^K y , MKCiCd, - \ /X ntftt.nc{KifU) iMowm i. ?
    CM9
    E ~ zzzz , / / / / xzzz »4
    M
    S4
    SJ
    IJ
    Lt
    1.1 zzzzzz
    Z%/ */// . z/zz >»z w/
    Anti-COVCDZ8
    AnthCOUCDZS
    8/8
    Fig. 10
    H-pH-TO
    ΙΐΜΊΜβΛφ
    -✓X—I
    Lrt IMmphfl] Iui^ik
    -♦-IPS
    -Q- LPS* nt«CS-TUO{1 -·- LPS+ iX-C«STMO{5 mykgl· -O- LPS * ftW-f£S-TMC (5 mjrtig |
    Tim* ·η«τ LP$ inaction (ih) /// ///
    7449540_1.txt <110> LEE, Sang Kyou <120> A Novel Fusion Protein Comprising Transcription Modulation of p65 and Protein Transduction Domain, and Uses Thereof <130> PP150138 <160> 6 <170> KopatentIn 2.0 <210> 1 <211> 187 <212> PRT <213> Amino acid sequence of p65 transcription modulation domain
    <400> 1 Asp Leu Phe 5 Pro Leu Ile Phe Pro Ser 10 Glu Pro Ala Gln 15 Ala Met 1 Asp Ser Gly Pro Tyr Val Glu Ile Ile Glu Gln Pro Lys Gln Arg Gly Met 20 25 30 Arg Phe Arg Tyr Lys Cys Glu Gly Arg Ser Ala Gly Ser Ile Pro Gly 35 40 45 Glu Arg Ser Thr Asp Thr Thr Lys Thr His Pro Thr Ile Lys Ile Asn 50 55 60 Gly Tyr Thr Gly Pro Gly Thr Val Arg Ile Ser Leu Val Thr Lys Asp 65 70 75 80 Pro Pro His Arg Pro His Pro His Glu Leu Val Gly Lys Asp Cys Arg 85 90 95 Asp Gly Tyr Tyr Glu Ala Asp Leu Cys Pro Asp Arg Ser Ile His Ser 100 105 110 Phe Gln Asn Leu Gly Ile Gln Cys Val Lys Lys Arg Asp Leu Glu Gln 115 120 125 Ala Ile Ser Gln Arg Ile Gln Thr Asn Asn Asn Pro Phe His Val Pro 130 135 140 Ile Glu Glu Gln Arg Gly Asp Tyr Asp Leu Asn Ala Val Arg Leu Cys 145 150 155 160 Phe Gln Val Thr Val Arg Asp Pro Ala Gly Arg Pro Leu Leu Leu Thr 165 170 175 Pro Val Leu Ser His Pro Ile Phe Asp Asn Arg 180 185
    <210> 2 <211> 561 <212> DNA <213> Nucleotide sequence of p65 transcription modulation domain <400> 2 atggacgatc tgtttcccct catctttccc tcagagccag cccaggcttc tgggccttat gtggagatca tcgaacagcc gaagcaacgg ggcatgcgat tccgctataa atgcgagggg cgctcagcgg gcagtattcc tggcgagaga agcacagata ccaccaagac acaccccacc atcaagatca atggctacac aggaccagga acagttcgaa tctccctggt caccaaggat
    Page 1
    Domain
    120
    180
    240
    7449540_1.txt ccacctcacc ggcctcatcc acatgaactt gtggggaagg actgccggga tggctactat 300 gaggctgacc tctgcccaga ccgcagtatc catagcttcc agaacctggg gatccagtgt 360 gtgaagaagc gagacctgga gcaagccatt agccagcgaa tccagaccaa caataacccc 420 tttcacgttc ctatagagga gcagcgcggg gactatgact tgaatgcagt gcgcctctgc 480 ttccaggtga cagtgcggga cccagcaggc aggcccctcc tcctgacccc tgtcctctca 540 catccgattt ttgataaccg g 561
    <210> 3 <211> 11 <212> PRT <213> Amino acid sequence of Hph-1 <400> 3 Tyr Ala Arg Val Arg Arg Arg Gly Pro Arg Arg 1 5 10 <210> 4 <211> 33 <212> DNA <213> Nucleotide sequence of Hph-1
    <400> 4 tatgcacgtg ttcggaggcg tggaccccgc cgc 33 <210> 5 <211> 235 <212> PRT <213> Amino acid sequence of nt-p65-TMD
    <400> 5 Ser Ser His 5 His His His His His 10 Ser Ser Gly Leu Val 15 Pro Met 1 Gly Arg Gly Ser His Met Ala Ser Gly Tyr Ala Arg Val Arg Arg Arg Gly 20 25 30 Pro Arg Arg Gly Gly Ser Asp Tyr Lys Asp Asp Asp Asp Lys Glu Phe 35 40 45 Met Asp Asp Leu Phe Pro Leu Ile Phe Pro Ser Glu Pro Ala Gln Ala 50 55 60 Ser Gly Pro Tyr Val Glu Ile Ile Glu Gln Pro Lys Gln Arg Gly Met 65 70 75 80 Arg Phe Arg Tyr Lys Cys Glu Gly Arg Ser Ala Gly Ser Ile Pro Gly 85 90 95 Glu Arg Ser Thr Asp Thr Thr Lys Thr His Pro Thr Ile Lys Ile Asn 100 105 110 Gly Tyr Thr Gly Pro Gly Thr Val Arg Ile Ser Leu Val Thr Lys Asp 115 120 125 Pro Pro His Arg Pro His Pro His Glu Leu Val Gly Lys Asp Cys Arg 130 135 140 Asp Gly Tyr Tyr Glu Ala Asp Leu Cys Pro Asp Arg Ser Ile His Ser 145 150 155 160
    Page 2
    7449540_1.txt
    Phe Gln Asn Leu Gly Ile Gln Cys Val Lys Lys Arg Asp Leu Glu Gln 165 170 175
    Ala Ile Ser Gln Arg Ile Gln Thr Asn Asn Asn Pro Phe His Val Pro 180 185 190
    Ile Glu Glu Gln Arg Gly Asp Tyr Asp Leu Asn Ala Val Arg Leu Cys 195 200 205
    Phe Gln Val Thr Val Arg Asp Pro Ala Gly Arg Pro Leu Leu Leu Thr 210 215 220
    Pro Val Leu Ser His Pro Ile Phe Asp Asn Arg
    225 230 235 <210> 6 <211> 708 <212> DNA <213> Nucleotide sequence of nt-p65-TMD <400> 6 atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat 60 atggctagcg gctatgcacg tgttcggagg cgtggacccc gccgcggcgg atccgactac 120 aaggacgacg atgacaagga attcatggac gatctgtttc ccctcatctt tccctcagag 180 ccagcccagg cttctgggcc ttatgtggag atcatcgaac agccgaagca acggggcatg 240 cgattccgct ataaatgcga ggggcgctca gcgggcagta ttcctggcga gagaagcaca 300 gataccacca agacacaccc caccatcaag atcaatggct acacaggacc aggaacagtt 360 cgaatctccc tggtcaccaa ggatccacct caccggcctc atccacatga acttgtgggg 420 aaggactgcc gggatggcta ctatgaggct gacctctgcc cagaccgcag tatccatagc 480 ttccagaacc tggggatcca gtgtgtgaag aagcgagacc tggagcaagc cattagccag 540 cgaatccaga ccaacaataa cccctttcac gttcctatag aggagcagcg cggggactat 600 gacttgaatg cagtgcgcct ctgcttccag gtgacagtgc gggacccagc aggcaggccc 660 ctcctcctga cccctgtcct ctcacatccg atttttgata accggtag 708
    Page 3
AU2016385177A 2016-01-06 2016-01-06 Novel fusion protein comprising transcription modulation domain of P65 and protein transport domain and use thereof Active AU2016385177B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2016/000104 WO2017119521A1 (en) 2016-01-06 2016-01-06 Novel fusion protein comprising transcription modulation domain of p65 and protein transport domain and use thereof

Publications (2)

Publication Number Publication Date
AU2016385177A1 true AU2016385177A1 (en) 2018-08-09
AU2016385177B2 AU2016385177B2 (en) 2023-10-19

Family

ID=59274225

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016385177A Active AU2016385177B2 (en) 2016-01-06 2016-01-06 Novel fusion protein comprising transcription modulation domain of P65 and protein transport domain and use thereof

Country Status (4)

Country Link
JP (1) JP7051687B2 (en)
AU (1) AU2016385177B2 (en)
CA (1) CA3010811A1 (en)
WO (1) WO2017119521A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723299B2 (en) * 2005-11-04 2010-05-25 Forhumantech. Co., Ltd. Methods for treating rheumatoid arthritis using a CTLA-4 fusion protein
EP3875474A1 (en) * 2010-08-20 2021-09-08 Good T Cells, Inc. A fusion protein having transcription modulating domain and a protein transduction domain, and an inhibitor for transcription factor function comprising the same
KR101525856B1 (en) * 2010-08-20 2015-06-04 연세대학교 산학협력단 A inhibitor for transcription factor of fusion protein comprising DNA binding domain of transcription factor and protein transduction domain

Also Published As

Publication number Publication date
JP7051687B2 (en) 2022-04-11
CA3010811A1 (en) 2017-07-13
WO2017119521A1 (en) 2017-07-13
AU2016385177B2 (en) 2023-10-19
JP2019507117A (en) 2019-03-14

Similar Documents

Publication Publication Date Title
Saeki et al. Identification, signaling, and functions of LTB4 receptors
JP6923485B2 (en) Peptides with anti-inflammatory activity and compositions containing them
Hodzic et al. IL-33 and the intestine: the good, the bad, and the inflammatory
Baksh et al. NFATc2-mediated repression of cyclin-dependent kinase 4 expression
Proost et al. Chemokine isoforms and processing in inflammation and immunity
Ozcan et al. Role of endoplasmic reticulum stress in metabolic disease and other disorders
Colazzo et al. Role of the cysteinyl leukotrienes in the pathogenesis and progression of cardiovascular diseases
Suryadinata et al. Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates
Andersson et al. HMGB1 as a DNA-binding cytokine
Harding et al. Cyclophilin, a primary molecular target for cyclosporine
Leo et al. Differential requirements for tumor necrosis factor receptor-associated factor family proteins in CD40-mediated induction of NF-κB and Jun N-terminal kinase activation
Bilsborough et al. Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis
US6413730B1 (en) Method for identifying compounds that inhibit or enhance activation of a transmembrane ligand for a receptor tyrosine kinase
Zhang et al. Effects and mechanisms of potent caspase-1 inhibitor VX765 treatment on collagen-induced arthritis in mice
Qin et al. Formylpeptide receptor 2: Nomenclature, structure, signalling and translational perspectives: IUPHAR review 35
Cai et al. Convergent synthesis of novel muramyl dipeptide analogues: inhibition of porphyromonas gingivalis-induced pro-inflammatory effects by high doses of muramyl dipeptide
Harama et al. A subcytotoxic dose of subtilase cytotoxin prevents lipopolysaccharide-induced inflammatory responses, depending on its capacity to induce the unfolded protein response
US11414467B2 (en) Fusion protein comprising transcription modulation domain of p65 and protein transduction domain, and uses thereof
Carlson et al. fMLP induces Hsp27 expression, attenuates NF-κB activation, and confers intestinal epithelial cell protection
Duggan et al. Total synthesis of the spider-venom peptide Hi1a
Hayakawa et al. Blunted activation of NF-κB and NF-κB-dependent gene expression by geranylgeranylacetone: involvement of unfolded protein response
Hwang et al. NFAT1 and JunB cooperatively regulate IL-31 gene expression in CD4+ T cells in health and disease
Penrose LTC 4 synthase: Enzymology, biochemistry, and molecular characterization
Vila et al. Alternative pathways driven by STING: From innate immunity to lipid metabolism
AU2016385177A1 (en) Novel fusion protein comprising transcription modulation domain of P65 and protein transport domain and use thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI U

Free format text: FORMER APPLICANT(S): LEE, SANG

PC1 Assignment before grant (sect. 113)

Owner name: GOOD T CELLS, INC.

Free format text: FORMER APPLICANT(S): INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

FGA Letters patent sealed or granted (standard patent)